Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18,755 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96.
Su B, Gao G, Wang M, Lu Y, Li L, Chen C, Chen Y, Song C, Yu F, Li Y, Liu Y, Luo Y, He H, Cheng C, Xu L, Zhang T, Sun L, Liu A, Xia W, Qin Y, Zhao Q, Wei H, Cai W, Chen Y, Zhang F, Wu H. Su B, et al. Among authors: zhao q. Lancet Reg Health West Pac. 2023 Apr 24;36:100769. doi: 10.1016/j.lanwpc.2023.100769. eCollection 2023 Jul. Lancet Reg Health West Pac. 2023. PMID: 37547039 Free PMC article.
Low prevalence of human leukocyte antigen-B*5701 in HIV-1-infected Chinese subjects: a prospective epidemiological investigation.
Zhang H, Zhang T, Zhao H, Han N, Zhou H, He Y, Zhao Q, Li H, Li H, Zhang M, Li J, Sun Y, Zhao K, Liu Q, Liu Z, Li Z, Xia W, Lan Y, Hu H, Cai W, Wu H. Zhang H, et al. Among authors: zhao k, zhao h, zhao q. AIDS Res Ther. 2015 Aug 19;12:28. doi: 10.1186/s12981-015-0064-9. eCollection 2015. AIDS Res Ther. 2015. PMID: 26300948 Free PMC article.
Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China.
Huang X, Xu L, Sun L, Gao G, Cai W, Liu Y, Ding H, Wei H, Ma P, Wang M, Liu S, Chen Y, Chen X, Zhao Q, Yu J, Song Y, Chen H, Wu H, Qin S, Li L. Huang X, et al. Among authors: zhao q. Front Pharmacol. 2019 Dec 11;10:1455. doi: 10.3389/fphar.2019.01455. eCollection 2019. Front Pharmacol. 2019. PMID: 31920648 Free PMC article.
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.
Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, Chen YY, Liu L, Wang H, He Y, Zheng YH, Li LH, Chen JF, Yu JH, Zhu B, Zhao M, Sun YT, Lun WH, Xia W, Sun LJ, Dai LL, Jiang TY, Wang MX, Zheng QS, Peng HY, Wang Y, Lu RJ, Hu JH, Xing H, Shao YM, Xie D, Zhang T, Zhang FJ, Wu H; TALENT Study Team. Su B, et al. Chin Med J (Engl). 2020 Nov 25;133(24):2919-2927. doi: 10.1097/CM9.0000000000001273. Chin Med J (Engl). 2020. PMID: 33252379 Free PMC article. Clinical Trial.
Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.
Su B, Yao C, Zhao QX, Cai WP, Wang M, Lu HZ, Mu TT, Chen YY, Liu L, Wang H, He Y, Zheng YH, Li LH, Chen JF, Yu JH, Zhu B, Zhao M, Sun YT, Lun WH, Zhang YH, Wang H, Xia W, Sun LJ, Dai LL, Jiang TY, Wang MX, Zheng QS, Peng HY, Wang Y, Hu M, Liu X, Lu RJ, Hu JH, Sun CC, Xing H, Shao YM, Xie D, Zhang T, Zhang FJ, Wu H. Su B, et al. J Infect. 2022 Sep;85(3):334-363. doi: 10.1016/j.jinf.2022.05.034. Epub 2022 Jun 1. J Infect. 2022. PMID: 35659547 No abstract available.
18,755 results
You have reached the last available page of results. Please see the User Guide for more information.